Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

July 2017

P&T Committee Updates


At the June 5th, 2017 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed three medications and decided the following:

P&T Committee Review and Decisions

Name

Description and Indication

Decision

Rayaldee (calcifediol) 

Rayaldee (calcifediol) is a vitamin D3 analog indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL.

  • Premium formulary: Continued coverage at non-preferred brand tier with prior authorization and quantity limit
  • Value formulary: Remains non-covered
  • Medicare Advantage Formulary: Remains non-covered

Zurampic (lesinurad) 

Zurampic (lesinurad) is a URAT1 inhibitor indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not yet achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.

  • Premium formulary: Continued coverage at non-preferred brand tier with prior authorization and quantity limit
  • Value formulary: Added to non-preferred brand tier with prior authorization and quantity limit
  • Medicare Advantage formulary: Added to non-preferred brand tier with prior authorization and quantity limit

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Webinars for New Sleep Diagnostic and Sleep Therapy Program

Eric Schultz Signs on for CEOs Against Stigma

CLINICIAN CORNER

Updates to Medical Policies

CVS Health–NovoLogix: Prior Authorization for Overlapping Medical/Pharmacy Drugs

Benefits of Medication Therapy Management Program

P&T Committee Updates

Specialty Pharmacy Program Updates

OFFICE ASSISTANT

ACA Risk Adjustment Data Validation: Medical Chart Requests Underway

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator